NCT01233687 - AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

AMG 102 and erlotinib

"Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg~The first cohort of patients in the phase I portion will start at dose level 0 of AMG102."

Trial Locations (1)

15232

University of Pittsburgh Cancer Institute, Pittsburgh